Hofmann-Lehmann R, Holznagel E, Aubert A, Ossent P, Reinacher M, Lutz H
Department of Internal Veterinary Medicine, University of Zurich, Switzerland.
Vet Immunol Immunopathol. 1995 May;46(1-2):127-37. doi: 10.1016/0165-2427(94)07012-v.
The efficacy and the long-term protection of a recombinant feline leukemia virus (FeLV) vaccine were determined in 30 specified pathogen free cats for over 3 years. At the same time, in order to specify the effects of feline immunodeficiency virus (FIV) on the immune system, one half of the cats (n = 15) were previously infected with the Swiss isolate FIV Zurich 2. The second half of the animals (n = 15) served as non-infected controls. Eighteen (nine FIV-negative, nine FIV-positive) vaccinated and 12 (six FIV-negative, six FIV-positive) non-vaccinated cats were intraperitoneally challenged with FeLV A. Seventeen of 18 vaccinated cats were protected against persistent viremia, while ten of 12 non-vaccinated controls became infected. An increase of antibodies against FeLV SU was found in all protected cats after the challenge exposure. No difference in vaccine efficacy was found between FIV-negative and FIV-positive animals. The whole group of cats was observed for over 3 years. There were no further vaccinations during this period. CD4+ and CD8+ cell subsets, clinical outcome and time of survival of the cats were recorded. FIV-negative and FIV-positive animals were kept in two different rooms. However, FeLV-negative and FeLV viremic cats were housed together in both rooms in order to imitate a natural FeLV exposure situation. Anti-recombinant FeLV SU antibodies were measured by enzyme-linked immunosorbent assay. Although a continuous decline of antibodies was found in FeLV vaccinated cats, they remained protected against constant FeLV challenge for over 3 years. FIV infection had a stronger effect on the depression of the CD4+:CD8+ ratio than FeLV infection. Within the group of FIV-positive cats, the FeLV-vaccinated animals had significantly better survival rates as well as better clinical and laboratory parameters. FIV- and FeLV-coinfected cats showed the lowest CD4+:CD8+ ratio, mainly caused by decreased CD4+ lymphocyte counts. CD8+ lymphocytes with strong fluorescence (CD8(high)) disappeared and cells with weak fluorescence (CD8(low)) appeared instead. Prevention of coinfection by immunizing FIV-positive cats against FeLV infection improved the clinical outcome and prolonged the cat's life expectancy.
在30只无特定病原体的猫身上对重组猫白血病病毒(FeLV)疫苗的疗效和长期保护作用进行了3年多的测定。同时,为了明确猫免疫缺陷病毒(FIV)对免疫系统的影响,将一半的猫(n = 15)预先感染瑞士分离株FIV苏黎世2。另一半动物(n = 15)作为未感染对照。18只(9只FIV阴性,9只FIV阳性)接种疫苗的猫和12只(6只FIV阴性,6只FIV阳性)未接种疫苗的猫经腹腔接种FeLV A。18只接种疫苗的猫中有17只受到保护,免受持续性病毒血症的影响,而12只未接种疫苗的对照猫中有10只被感染。在攻击暴露后,所有受保护的猫体内抗FeLV SU抗体均有所增加。在FIV阴性和FIV阳性动物之间未发现疫苗效力有差异。对整组猫进行了3年多的观察。在此期间未进行进一步的疫苗接种。记录了猫的CD4 +和CD8 +细胞亚群、临床结果和存活时间。FIV阴性和FIV阳性动物饲养在两个不同的房间。然而,FeLV阴性和FeLV病毒血症的猫被安置在两个房间一起饲养,以模拟自然的FeLV暴露情况。通过酶联免疫吸附测定法测量抗重组FeLV SU抗体。尽管在接种FeLV疫苗的猫中发现抗体持续下降,但它们在3年多的时间里仍受到保护,免受持续的FeLV攻击。FIV感染对CD4 +:CD8 +比值降低的影响比FeLV感染更强。在FIV阳性猫组中,接种FeLV疫苗的动物具有明显更好的存活率以及更好的临床和实验室参数。FIV和FeLV共感染的猫显示出最低的CD4 +:CD8 +比值,主要是由于CD4 +淋巴细胞计数减少。具有强荧光的CD8 +淋巴细胞(CD8(高))消失,取而代之的是具有弱荧光的细胞(CD8(低))。通过给FIV阳性猫接种疫苗预防FeLV感染可改善临床结果并延长猫的预期寿命。